Compare GNT & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GNT | CRBU |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.6M | 138.3M |
| IPO Year | N/A | 2021 |
| Metric | GNT | CRBU |
|---|---|---|
| Price | $8.64 | $1.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.75 |
| AVG Volume (30 Days) | 40.2K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 6.61% | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ 0.95 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.63 |
| Revenue Next Year | N/A | $10.93 |
| P/E Ratio | $9.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.68 | $1.22 |
| 52 Week High | $9.38 | $3.53 |
| Indicator | GNT | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 36.82 | 32.86 |
| Support Level | $7.81 | N/A |
| Resistance Level | $8.79 | $1.76 |
| Average True Range (ATR) | 0.14 | 0.07 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 10.61 | 6.25 |
GAMCO Natural Resources, Gold & Income Trust is a non-diversified closed-end management investment company. The company's primary investment objective is to provide a high level of current income from interest, dividends, and options premiums with its secondary objective being capital appreciation. Under normal market conditions, the company invests majority of its assets in securities of companies principally engaged in the natural resources and gold industries, and also engages in writing covered call options on the underlying equity securities. Its portfolio consists of securities from different sectors such as metals and mining, energy and energy services, specialty chemicals, agriculture, healthcare, machinery, food and beverage, and others.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.